Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

COPD Research Forum

European Respiratory Society (ERS) kongres 2024

Transforming T2DM Management Paradigm with Combination Injectables

Transforming T2DM Management Paradigm with Combination Injectables

2024 ESC Guidelines

Taltuta RSV-kauden kaaos

▼ Tähän lääkevalmisteeseen kohdistuu lisäseuranta.

Type 1 Diabetes: Mechanism of Beta Cell Loss Caused by Autoimmune T Cells

This animated video provides an overview of the key immunological processes that underlie the development of autoimmunity in T1D. Autoreactive T cells drive pancreatic beta-cell destruction, resulting in insulin deficiency and, ultimately, hyperglycemia and symptoms of T1D.

Dia-Tour: Navigating New Destinations in Diabetes Management

Dia-Tour: Navigating New Destinations in Diabetes Management

Dia-Tour: Navigating New Destinations in Diabetes Management

La última innovación de los expertos en probióticos: ENTEROBIOTICS

Principales características de la última innovación de los expertos en probióticos, Enterobiotics Baby Comfort.

Real-World Insights on Managing Immune-Mediated Thrombotic Thrombocytopenic Purpura with Caplacizumab

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by severe deficiency of the enzyme ADAMTS13, leading to the formation of microthrombi in small blood vessels. This condition requires prompt and effective treatment to prevent serious complications.

Caplacizumab is an innovative nanobody® and cornerstone in the treatment of iTTP.1 This article delves into real-world data from Belgian hospitals on the use of caplacizumab, highlighting its efficacy, safety, and impact on patient outcomes.2